Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. is a leading commercial-stage medical device company based in Silicon Valley, focused on transforming the lives of individuals suffering from epilepsy. Founded with the mission to design, develop, manufacture, and market implantable devices for neurological disorders, NeuroPace has made significant strides in the field of responsive neurostimulation.
At the core of NeuroPace's innovation is the RNS® System. This award-winning technology, akin to a pacemaker for the heart, is the world's first and only medical device capable of monitoring and responding to brain activity in real-time. The RNS® System is specifically designed to treat epilepsy, a neurological disorder that affects approximately 1% of the global population, by reducing or eliminating debilitating seizures. The system is primarily used in hospital facilities, particularly Level 4 Comprehensive Epilepsy Centers (CECs).
Beyond epilepsy, the promise of responsive neurostimulation extends to several other disabling medical conditions, potentially improving the quality of life for millions worldwide. NeuroPace is recognized for its patient-centric approach and continuous advancements in the field of neurological treatments.
Recent achievements include the RNS® System being featured in over 50 scientific presentations and posters, underscoring its impact and the ongoing research dedicated to improving its efficacy. The company also maintains significant partnerships and collaborations to further its mission and ensure the RNS® System remains at the forefront of medical innovation.
Financially, NeuroPace derives nearly all its revenue from the sales of the RNS® System, highlighting the product's centrality to the company’s business model. With a strong focus on patient outcomes and continuous technological advancement, NeuroPace is well-positioned to lead in the field of neurological disorder treatments.
NeuroPace (Nasdaq: NPCE), a medical device company focused on epilepsy treatment, has announced its participation in two major healthcare conferences this September. The company will:
- Attend the Wells Fargo 2024 Healthcare Conference on September 4 in Boston, hosting one-on-one investor meetings
- Present at the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6 in New York
At the Morgan Stanley conference, CEO Joel Becker and CFO Rebecca Kuhn will participate in a fireside chat on September 6 at 8:30am ET, which will be webcast live. They will also host one-on-one investor meetings. A replay of the fireside chat will be available on NeuroPace's Investor website.
NeuroPace (NPCE) reported strong Q2 2024 financial results, with revenue growing 17% to $19.3 million compared to Q2 2023. The company increased its full-year 2024 revenue guidance to $76-$78 million. Key highlights include:
- Expanded gross margin to 73.4% from 72.5% in Q2 2023
- Decreased cash burn to $4.0 million from $4.4 million in Q2 2023
- Completed initial hiring of expanded commercial organization
- Continued progress in executing growth strategy, including expanding commercial organization and increasing active prescribing epileptologists
NeuroPace remains focused on generating broader adoption of RNS therapy and closing the treatment gap for drug-resistant epilepsy patients.
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, has announced its plans to release second quarter 2024 financial results on August 13, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day to discuss the results.
Investors can access the live webcast at https://viavid.webcasts.com/starthere.jsp?ei=1677457&tp_key=a97b4f856d or join via telephone by dialing +1-877-407-3982 (Conference ID: 13747326). The webcast will be archived on NeuroPace's investor relations website for at least 90 days after the event.
NeuroPace (Nasdaq: NPCE), a medical device company specializing in epilepsy treatment, announced its participation in two healthcare conferences in May 2024. The company will join the Wells Fargo 2024 West Coast MedTech Tour on May 28 at 2:30pm PT in Menlo Park, CA, featuring a fireside chat with investors.
Additionally, NeuroPace will present at the Leerink Partners Healthcare Crossroads Conference from May 28-30 in Austin, TX. CEO Joel Becker will deliver a corporate presentation on May 30 at 8:00am CT, and the company will engage in one-on-one meetings with investors. The presentation will be available via live webcast and replay on NeuroPace’s Investor website.
NeuroPace, Inc. (NPCE) reported total revenue of $18.1 million in Q1 2024, a 25% increase from Q1 2023. The company extended its term loan maturity, maintained full-year revenue guidance of $73 to $77 million, and achieved growth in RNS System and DIXI Medical sales. Operating expenses were managed effectively, resulting in decreased losses compared to the prior year. The company remains focused on expanding market reach and increasing access to RNS therapy for epilepsy patients.
FAQ
What is the current stock price of Neuropace (NPCE)?
What is the market cap of Neuropace (NPCE)?
What is NeuroPace, Inc. known for?
What medical condition does the RNS® System primarily target?
Where is NeuroPace, Inc. based?
How does the RNS® System work?
Who are the primary customers for the RNS® System?
What recent achievements has NeuroPace made?
How does NeuroPace generate revenue?
Can the RNS® System treat conditions other than epilepsy?
What makes the RNS® System unique?
Who can be contacted for investor-related inquiries at NeuroPace?
